Objective-To investigate serum soluble interleukin-2 receptor (sIL-2R) in familial Mediterranean fever (FMF) and assess its role in acute FMF crisis. Methods-Serum sIL-2R concentrations were measured in patients with FMF during acute crises and during inactive periods of the disease, using an immunoenzymatic assay kit. Twenty four FMF patients during acute crisis (active FMF), 17 patients with inactive FMF, 24 healthy controls, and 20 active patients with rheumatoid arthritis (as a disease control group) were studied. Results-Serum sIL-2R concentrations were increased during an acute FMF crisis compared with the values in inactive FMF patients and healthy controls (P = 0.0105 and P = 0.0012 respectively), while there was no significant difference between the mean values in active FMF and rheumatoid arthritis patients (P = 0.7325). In 14 of the FMF group whose blood samples were available in both active and inactive phases, sIL-2R concentrations were significantly higher in an acute attack than in an attack-free period (P = 0.027). Conclusions-An increase in sIL-2R may be a result of hyperreactivity of IL-2R-expressing cells during an acute inflammatory attack of FMF.
Familial Mediterranean fever (FMF) is an autosomal recessive disorder of unknown aetiology which is characterised by recurrent painful attacks of polyserositis (peritonitis, pleuritis) usually accompanied by fever Serum sIL-2R concentrations were significantly higher in the active FMF group than in the healthy controls (P = 0.0012, Mann Whitney U test), while there was no significant difference between the inactive group and normal controls (P = 0.11, Mann Whimtney U test). There was also a significant difference between the sIL-2R levels of 24 patients with active and 17 with inactive FMF (P = 0.0105, Mann Whitney U test). Figure 2 shows sIL-2R concentrations of the 14 patients with FMF whose sera were available in both active and inactive phases. There was a significant difference between sIL-2R concentrations of these patients in their active and inactive phases (P = 0.027, Wilcoxon test). Twenty patients with active rheumatoid arthritis also had significantly raised serum sIL-2R concentrations when compared with 24 healthy controls (P = 0.000 1, Mann Whitney U test). Serum slL-2R concentrations were found to be very high in four patients with inactive FMF (figs 1 and 2). These patients had no specific clinical symptoms during the inactive phase. Interestingly, during an acute crisis their sIL-2R concentrations were even higher than during the inactive periods (fig 2) , though again, no specific clinical symptoms were noted.
No significant correlation was found between sIL-2R and C reactive protein concentrations in patients with active or inactive FMF (r = 0.257, P > 0.05, and r = 0.088, P > 0.05, respectively). However there was a significant correlation between ESR and sIL-2R concentrations in patients with active FMF (r = 0.552, P < 0.01). The ESR in patients with active FMF also correlated significantly with C reactive protein (r = 0.414, P < 0.05).
There was no significant difference in sIL-2R concentrations between patients with active FMF (24) and patients with active rheumatoid arthritis (20) (P = 0.732, Mann Whitney U test).
Discussion
High serum concentrations of sIL-2R have been reported in patients with various autoimmune diseases, including rheumatoid arthritis" 12 and systemic lupus erythematosus." Correlation between sIL-2R levels and disease activity have also been described in these diseases."3 14 Although its immunopathogenesis remains unknown, FMF is a disease characterised by inflammatory attacks of serosal membranes and joints accompanied by fever. The All of our patients in the inactive phase were receiving colchicine prophylaxis. It is not known whether colchicine affects sIL-2R concentrations. sIL-2R measurement was available in only two inactive patients without colchicine prophylaxis, who were not included in this study (one with an sIL-2R value of 420 U ml-', the other 667 U ml-'). In order to investigate a colchicine effect, sIL-2R concentrations in two groups of inactive patients who are either on colchicine prophylaxis or not should be compared.
